Related Experiment Videos
Pharmacotherapy for Alzheimer's disease: 2002
1Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. knopman@mayo.edu
Clinical Neuropharmacology
|April 3, 2003
Summary
Research reviews Alzheimer's disease (AD) therapies, including cholinesterase inhibitors and emerging secretase-targeted strategies. Some approaches like amyloid-beta immunization showed toxicity, while others yielded disappointing results, necessitating further investigation for effective AD treatments.
Area of Science:
- Neuroscience and Pharmacology
- Alzheimer's Disease Therapeutics
Background:
- Growing interest in Alzheimer's disease (AD) therapy drives research.
- Cholinesterase inhibitors' long-term effects and symptomatic impact are better understood.
- Basic science advances offer new therapeutic targets, including secretases in amyloid precursor protein metabolism.
Purpose of the Study:
- To review current and emerging therapeutic strategies for Alzheimer's disease.
- To discuss the outcomes of various investigational approaches.
- To provide an overview of potential future therapeutic agents.
Main Methods:
- Literature review of published studies on Alzheimer's disease therapies.
- Analysis of clinical trial outcomes and basic science research.
- Discussion of both successful and disappointing therapeutic avenues.
Main Results:
- Cholinesterase inhibitors' efficacy and long-term effects have been refined.
- Secretase-targeted strategies show promise but require further research.
- Amyloid-beta immunization was halted due to toxicity; estrogen and anti-inflammatory therapies yielded disappointing results.
Conclusions:
- The therapeutic landscape for Alzheimer's disease is dynamic, with ongoing research into novel targets.
- Past and current investigations highlight the complexities and challenges in developing effective AD treatments.
- Continued exploration of various agents is crucial for advancing Alzheimer's disease care.